Juncell Therapeutics Showcases TIL Therapy Innovations at Asia Financial Forum 2026 Following Hong Kong IPO Filing

Source: Yangtze Evening News

Recently, the 19th Asian Financial Forum, jointly organized by the Hong Kong Special Administrative Region Government and the Hong Kong Trade Development Council, was held at the Hong Kong Convention and Exhibition Center. This year's forum introduced the "Global Industry Summit" for the first time, focusing on high-growth, high-value industries such as biopharmaceuticals and healthcare. As one of the key biopharmaceutical companies showcased at the forum, Juncell Therapeutics presented its technological breakthroughs, product pipeline, and commercialization prospects in the field of TIL innovative therapies.

It is reported that Juncell Therapeutics submitted its IPO application to the Hong Kong Stock Exchange last December. Previously, the company completed multiple rounds of financing totaling nearly 800 million yuan, with multiple rounds of support from well-known domestic biopharmaceutical funds such as C-Bridge Capital, Originate Point, Fosun Healthcare Fund, and Huangpu Pharmaceutical Fund. The most recent round was the Series C financing completed in November 2025, with the company's current valuation reaching 2.137 billion yuan.